Bernstein analyst Lance Wilkes downgraded Agilon Health (AGL) to Market Perform from Outperform with a price target of $1.40, down from $4. The firm cites the company’s worse than expected margin pressure for the downgrade. Agilon’s margin challenges reduce its capital cushion and increases its cost of capital, which creates an uncertain growth outlook, the analyst tells investors in a research note. Bernstein does not see the company as representing a strategically valuable asset that could be attractive to buyers.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGL:
- Agilon Health Faces Leadership and Performance Challenges Amid Hold Rating
- Agilon Health price target lowered to $1.10 from $2.40 at Jefferies
- Agilon Health price target lowered to $1 from $5 at Baird
- Agilon Health’s Earnings Call: Challenges and Optimism
- Agilon Health Faces Uncertainty Amid RAF Challenges and Leadership Changes